CULLINAN THERAPEUTICS, INC. (CGEM) Price / Book
- 2026-09-03: Price/Book Ratio 4.43.
- 2026-06-30: Price/Book Ratio 3.64.
- 2026-03-31: Price/Book Ratio 2.38.
- 2025-12-31: Price/Book Ratio 1.53.
Historical market capitalization divided by filed shareholder equity.
- Available history
- 2021-03-31 to 2026-09-03
- Data captured
Historical Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |